Sugi Predict

Sugi Predict / Compounds / SCHEMBL1065312

SCHEMBL1065312

SCHEMBL1065312

CC(C)(C)OC(=O)NCCc1ccc(Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.55
▸ CA1 P00915 2/20 0.55
▸ NAMPT P43490 1/20 0.54
▸ FPR2 P25090 4/20 0.50
▸ CTSS P25774 1/20 0.50
▸ CTSK P43235 1/20 0.50
▸ NPC1 O15118 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ FPR3 P25089 3/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.47
▸ CNR1 P21554 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ NQO2 P16083 1/20 0.46
▸ PLAAT3 P53816 1/20 0.46
▸ PLAAT5 Q96KN8 1/20 0.46
▸ PLAAT2 Q9NWW9 1/20 0.46
▸ PLAAT4 Q9UL19 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551512 0.91 CA1 (0.53) CA2CA1NAMPTFPR2CTSS
SCHEMBL15584901 0.90 CA2 (0.53) CA2CA1NAMPTFPR2CTSS
SCHEMBL21482939 0.90 TDP1 (0.53) CA2CA1FPR2CTSSCTSK
SCHEMBL12387513 0.88 CA2 (0.55) CA2CA1NAMPTCTSKNPC1
SCHEMBL24669430 0.87 NAMPT (0.55) CA2CA1NAMPTFPR2FPR3
SCHEMBL30754110 0.86 NPC1 (0.47) CA2CA1NAMPTFPR2CTSS
SCHEMBL12283041 0.86 NPC1 (0.60) CA2CA1NAMPTNPC1RAB9A
SCHEMBL1569661 0.86 CA2 (0.56) CA2CA1NAMPTCTSKNPC1
SCHEMBL27741035 0.86 CA2 (0.56) CA2CA1NAMPTCTSKNPC1
SCHEMBL100146 0.86 KDM4E (0.60) CA2CA1NAMPTCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
EP-3681875-B1 CYCLIC PEPTIDE ANTIBIOTICS HOFFMANN LA ROCHE (CH) 2026-01-14 — — EP disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
US-20250304590-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS Enterprise Therapeutics Limited (GB) 2025-10-02 — — US disclosed
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AMTIXBIO CO., LTD. (KR) 2025-09-11 — — US disclosed
EP-4608810-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-09-03 — — EP disclosed
US-12371436-B2 Substituted benzodiazoliums as ENaC inhibitors Enterprise Therapeutics Limited (GB) 2025-07-29 — — US disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
CN-119751307-A Preparation method of ilast and intermediate thereof 苏州华先医药科技有限公司 2025-04-04 — — CN disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 — — US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 — — EP disclosed
WO-2000006537-A1 N-SUBSTITUTED SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 — — WO disclosed
WO-2000006176-A1 AMIDOPHOSPHATE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 — — WO disclosed
WO-2000006083-A2 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 — — WO disclosed
EP-0976744-A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity ELI LILLY AND COMPANY (US) 2000-02-02 — — EP disclosed
EP-0903349-A2 CCR-3 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 1999-03-24 — — EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 — — WO disclosed
EP-0860428-A2 Sulphonamide derivatives ELI LILLY AND COMPANY (US) 1998-08-26 — — EP disclosed
WO-1998033496-A1 SULPHONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 1998-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CA2 4617/4885CA1 4622/4885NAMPT 1694/4885
US-12371436-B2 Substituted benzodiazoliums as ENaC inhibitors NHERF1, SCNN1B, SCNN1A CA2 128/4885CA1 3948/4885NAMPT 1428/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA2 4617/4885CA1 4622/4885NAMPT 1694/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CA2 4610/4885CA1 4831/4885NAMPT 1628/4885
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AADAT, AADAC, AHR CA2 1311/4885CA1 3322/4885NAMPT 3916/4885
US-20250304590-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS NHERF1, SCNN1B, SCNN1A CA2 147/4885CA1 4227/4885NAMPT 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback